论文部分内容阅读
目的探讨血栓通注射液对晚期血吸虫病肝纤维化患者的疗效及患者肝纤维化指标影响。方法 120例晚期血吸虫病肝纤维化患者,随机分为观察组(66例)和对照组(54例)。对照组患者给予常规保肝治疗,观察组患者在对照组基础上给予血栓通注射液。比较两组临床疗效、血清生化指标、肝纤维化指标以及不良反应。结果观察组治疗总有效率显著高于对照组(P<0.05);两组患者治疗前TBIL、ALT、AST水平比较,差异无统计学意义(P>0.05),治疗后两组患者血清TBIL、ALT、AST水平均显著降低(P<0.05),且治疗后观察组TBIL、ALT、AST水平显著低于对照组(P<0.05);治疗前两组患者肝纤维化指标比较,差异无统计学意义(P>0.05),治疗后两组肝纤维化指标均显著降低(P<0.05),且治疗后观察组肝纤维化指标显著低于对照组(P<0.05)。结论血栓通注射液能够有效提高血吸虫病肝纤维化患者的临床疗效,促进患者肝功能以及肝纤维化病情的改善,用药安全可靠,值得临床推广。
Objective To investigate the effect of Xueshuantong injection on patients with advanced liver fibrosis due to schistosomiasis and the influence of liver fibrosis index. Methods 120 cases of advanced schistosomiasis patients with liver fibrosis were randomly divided into observation group (66 cases) and control group (54 cases). Patients in the control group were given conventional hepatoprotective therapy. Patients in the observation group were given Xueshuantong Injection on the basis of the control group. The clinical efficacy, serum biochemical indexes, liver fibrosis indexes and adverse reactions were compared between the two groups. Results The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). There was no significant difference in the levels of TBIL, ALT and AST between the two groups before treatment (P> 0.05) (P <0.05). After treatment, the levels of TBIL, ALT and AST in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in the indexes of liver fibrosis between the two groups before treatment (P <0.05). The indexes of hepatic fibrosis in both groups were significantly decreased after treatment (P <0.05), and the indexes of hepatic fibrosis in the observation group after treatment were significantly lower than those in the control group (P <0.05). Conclusion Xueshuantong Injection can effectively improve the clinical efficacy of schistosomiasis patients with liver fibrosis and promote the improvement of liver function and liver fibrosis in patients with safe and reliable medication, which is worthy of clinical promotion.